A Phase 2 interventional study of Part 1, JM-010 component Group A and Part 1, JM-010 component Group B in Dyskinesias and Parkinson Disease, sponsored by Bukwang Pharmaceutical. Terminated at 2 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-06-17.
Sponsored by Bukwang Pharmaceutical · Phase 2, Interventional, and Treatment
This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2 clinical trial of JM-010 in patients with Parkinson's Disease.
This is a two-part, Phase 2, double-blind, placebo-controlled, randomized, multicentre study.
Subjects with a diagnosis of PD and dyskinesias in PD will complete a Screening Visit to assess eligibility to participate in the study.
Exclusion Criteria:
Other criteria related to other medical conditions to be referred to the protocol.
Part 1, JM-010 component Group A
Drug: Part 1, JM-010 component Group A
Part 1, JM-010 component Group B
Drug: Part 1, JM-010 component Group B
Part 1, JM-010 component Group C
Drug: Part 1, JM-010 component Group C
Part 1, Placebo Group
Drug: Part 1, Placebo Group
Part 2, JM-010 combination Group A
Drug: Part 2, JM-010 combination Group A
Part 2, JM-010 combination Group B
Drug: Part 2, JM-010 combination Group B
Part 2, JM-010 component Group C
Drug: Part 2, JM-010 component Group C
Part 2, Placebo Group
Drug: Part 2, Placebo Group
JM-010 component Group A
JM-010 component Group B
JM-010 component Group C
Placebo Group
JM-010 combination Group A
JM-010 combination Group B
JM-010 component Group C
Placebo Group
Unified Dyskinesia Rating Scale (UDysRS)
Unified Dyskinesia Rating Scale (Scoring range: 0-104), higher score indicates more severe dyskinesia
Time frame: Week 12
Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Movement Disorder Society Unified Parkinson's Disease Rating Scale (Part III Scoring range: 0-137), higher score indicates more severe motor impairment
Time frame: Week 12
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bukwang Pharmaceutical